Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online November 22 in Nature.

Human cells contain 48 proteins that are known to depend on complexes of iron and sulfur to function. Dismantled whenever they encounter , these iron-sulfur clusters must be constantly replaced if normal cells are to survive in high-oxygen environments like the lungs, and even more so if are to grow with abnormal speed.

The current study shows that lung adenocarcinoma cells survive this oxygen threat by producing more of a protein called NFS1, which harvests sulfur from the amino acid cysteine to make iron-sulfur clusters. The researchers also found that that have spread to the lungs dial up NFS1 production upon arriving in a high-oxygen environment, while cells remaining in the breast do not.

"Our data support the notion that NFS1 provides a central protection for cancer cells against oxygen, and we hope to find ways to take it away," says lead study author Richard Possemato, PhD, assistant professor in the Department of Pathology at NYU School of Medicine.

In a genetic trick, the research team used short hairpin RNAs to switch off 2,752 genes related to cell metabolism, including iron and sulfur biochemistry, one by one. They found that many genes which were essential to survival in high oxygen levels were not as important in low oxygen.

Strikingly, the NFS1 gene was the most essential for survival at the elevated oxygen level present in the lungs, but not at the much lower oxygen level encountered by cells under the skin. When the researchers injected cancer cells with or without NFS1 under the skin of mice, a low oxygen environment, they grew equally well. But the same cells failed to form tumors in the lungs. Consistent with these findings in mice, analysis of human datasets revealed that NFS1 levels were higher in lung adenocarcinoma cells than in nearby, normal lung tissue.

Two New Ways to Stop Lung Cancer Growth

NFS1 may be vital to cancer cell survival in two ways, say the authors. If NFS1 is not active enough to keep up with the oxygen-mediated destruction of iron-sulfur clusters, cancer cells can run out of key building blocks for important proteins and just stop multiplying, researchers found.

Alternatively, the number of iron-sulfur clusters may serve as a sensor of iron levels. When clusters dip too low, say the authors, cells "think" they are short on iron, and free more from the molecules that store it. In studies of cultured cancer , the Perlmutter Cancer Center team found that this build-up of "free" iron causes the production of (ROS) that damage cell membranes and trigger a type of cell death called ferroptosis. The authors note that future work will be needed to confirm this effect in live animals.

"Our study suggests that future anti-cancer treatments that deprive of antioxidant protection against ROS can be combined with drugs that block NFS1, promoting cell death by iron-mediated toxicity, even in tumors that are at low oxygen," says Possemato.

As a next step, the research team is screening for experimental compounds that block the ability of NFS1 to feed the production of iron-sulfur clusters.

Explore further: Team identifies protein key to cancer cells ability to spread

More information: NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis, Nature (2017). nature.com/articles/doi:10.1038/nature24637

Related Stories

Team identifies protein key to cancer cells ability to spread

November 17, 2017
University of Guelph scientists have made a discovery that could reduce the spread of cancer by hindering a protein that binds cancer cells together and allows them to invade tissues.

New system finds and targets vulnerabilities in lung cancer cells

October 2, 2017
Genetic changes that help lung cancer thrive also make it vulnerable to a promising experimental drug, according to a study led by researchers from Perlmutter Cancer at NYU Langone Health, and published online October 2 in ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.